
Jonathan Halperin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6376151/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2006, 37, 577-617.	1.0	1,510
2	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375, 2423-2434.	13.9	1,265
3	Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2014, 312, 1988.	3.8	765
4	Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2008, 39, 1647-1652.	1.0	450
5	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Circulation, 2006, 113, .	1.6	416
6	OCT-Based Diagnosis and Management of STEMI Associated With Intact Fibrous Cap. JACC: Cardiovascular Imaging, 2013, 6, 283-287.	2.3	167
7	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
8	Occult Pseudoxanthoma Elasticum in Patients with Premature Cardiovascular Disease. New England Journal of Medicine, 1993, 329, 1237-1239.	13.9	115
9	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation, 2017, 135, 323-333.	1.6	86
10	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. Thrombosis and Haemostasis, 2017, 117, 2376-2388.	1.8	84
11	Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. European Heart Journal, 2014, 35, 242-249.	1.0	82
12	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Thrombosis and Haemostasis, 2016, 115, 1240-1248.	1.8	64
13	Aspirin in the Prevention of Coronary Disease. New England Journal of Medicine, 1989, 321, 183-185.	13.9	60
14	Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. American Journal of Cardiology, 1999, 83, 453-455.	0.7	60
15	Left Ventricular Thrombus Following Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1010-1022.	1.2	53
16	Addressing Resource Allocation Issues in Recommendations From Clinical Practice Guideline Panels. Chest, 2006, 129, 182-187.	0.4	50
17	Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty. Thrombosis and Haemostasis, 2012, 108, 86-93.	1.8	20
18	Persistence with Dabigatran Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Gloria-AF Registry. Blood, 2016, 128, 2616-2616.	0.6	12

JONATHAN HALPERIN

#	Article	IF	CITATIONS
19	RATES OF STROKE AND BLEEDING WITH DABIGATRAN 150 AND 110 MG BID IN CLINICAL PRACTICE: THE GLORIA-AF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 541.	1.2	11
20	Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation. Current Cardiology Reviews, 2014, 10, 297-302.	0.6	11
21	Bicuspid Pulmonic Valve. Journal of the American College of Cardiology, 2009, 54, e5.	1.2	10
22	Rhythm Control for Management of Patients With Atrial Fibrillation: Balancing the Use of Antiarrhythmic Drugs and Catheter Ablation. Clinical Cardiology, 2011, 34, 23-29.	0.7	10
23	Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and metaâ€analysis. Cardiovascular Therapeutics, 2018, 36, e12457.	1.1	8
24	Characteristics and 2â€year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIAâ€AF. ESC Heart Failure, 2020, 7, 2679-2689.	1.4	7
25	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). American Journal of Cardiology, 2019, 123, 355-360.	0.7	6
26	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically III Patients in the MAGELLAN and MARINER Trials. Circulation, 2022, 145, 1471-1479.	1.6	6
27	CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL. Journal of the American College of Cardiology, 2013, 61, E282.	1.2	2
28	Acute effects of oral labetalol on myocardial conduction after coronary artery bypass grafing. Clinical Pharmacology and Therapeutics, 1984, 35, 454-460.	2.3	1
29	PREDICTORS OF ANTICOAGULANT PRESCRIPTION IN PATIENTS WITH ATRIAL FIBRILLATION IN NORTH AMERICA: THE GLORIA-AF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 413.	1.2	1
30	PHYSICIAN CHOICE OF DISCHARGE ANTITHROMBOTIC REGIMEN IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION BASED ON BLEEDING AND ISCHEMIC RISK ASSESSMENT: RESULTS FROM AVIATOR MULTI-CENTER REGISTRY. Journal of the American College of Cardiology, 2014, 63, A1816.	1.2	0
31	Safety of Left Atrial Appendage Closure in Patients with Low Ejection Fraction. Journal of Cardiac Failure, 2015, 21, S104.	0.7	0
32	IMPACT OF LEFT VENTRICULAR DYSFUNCTION ON OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE AVIATOR REGISTRY. Journal of the American College of Cardiology, 2015, 65, A1922.	1.2	0
33	SEX DIFFERENCES IN ANTITHROMBOTIC THERAPY: OBSERVATIONS FROM THE GLORIA-AF REGISTRY PROGRAM. Journal of the American College of Cardiology, 2016, 67, 794.	1.2	0
34	PERSISTENCE WITH THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION: THE GLORIA-AF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 374.	1.2	0
35	OPTICAL COHERENCE TOMOGRAPHY OF CULPRIT LESIONS IN PATIENTS WITH PRIOR CEREBROVASCULAR EVENTS COMPARED TO CONTROLS. Journal of the American College of Cardiology, 2017, 69, 1832.	1.2	0
36	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. Journal of the American Heart Association, 2021, 10, e022485.	1.6	0

#	Article	IF	CITATIONS
37	Cardiology Fellowship Program DirectorÂWellness. Journal of the American College of Cardiology, 2021, 78, 1727-1729.	1.2	0